Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation

Seoul National University

Status

Terminated

Conditions

Atrial Fibrillation Paroxysmal

Atrial Fibrillation New Onset

Treatments

Drug: Amiodarone, diltiazem or esmolol

Study type

Interventional

Funder types

Other

Identifiers

NCT05950971

Postoperative NOAF

Details and patient eligibility

About

Adult patients who are diagnosed new onset atrial fibrillation with rapid ventricular response within 7 days after non-cardiac non-thoracic surgery are enrolled.

Full description

After randomization, they are allocated to rhythm control strategy group or rate control strategy group. In rhythm control strategy group, patients are given amiodarone primarily for the purpose of sinus conversion of cardiac rhythm. In rate control strategy group, patients are given diltiazem or esmolol for the purpose of rate control. the rate of sinus conversion within 48 hours after treatment are compared.

Enrollment

1 patient

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Older than 18 years
Newly diagnosed atrial fibrillation or flutter
Patients with atrial fibrillation or flutter that occurred within 7 days after non-cardiac non-thoracic surgery
Atrial fibrillation or flutter with rapid ventricular response(HR ≥110/min)
Patients without hemodynamic instability (MBP≥65mmHg with norepinephrine continuous infusion less than 5mcg/min or without vasopressor support)

Exclusion criteria

Atrial fibrillation or flutter prolonged more than 48 hours without anticoagulation
Patients who have decreased cardiac function or heart failure (EF <40%)
Patients who have cardiac conduction disorder, QT prolongation(QTc ≥500ms)